Pre-treatment with either u-PA (20 μg ml−1) or u-PAR (20 μg ml−1) function-blocking mAbs or the selective u-PA inhibitors, amiloride (10 mg ml−1) and WXC-340 (0.3 mg ml−1) partially impaired LPS-enhanced tumour cell invasion (P<0.05 compared to cells treated with LPS or LPS plus isotype mAb control) (Figure 4B and C). Here, PLAU is linked to neoplasm.